Sponsored Links
| Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy Of Rexin-G In Metastatic Pancreas Cancer: All Endpoints Achieved |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Read more: Pharma Industry / Biotech Industry News From Medical News Today
|